[Alpha Tau in Alpha Tau] Alpha Tau receives FDA Clearance to complete enrollment in REGAIN Recurrent Glioblastoma Trial and add two U.S. clinical sites; early interim results showed 100% local disease control

Jerusalem, June 11, 2026 — Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”, or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company to proceed with enrollment of the final seven patients in its U.S. REGAIN (Recurrent Glioblastoma Alpha-DaRT Intratumoral Therapy) trial, following the FDA’s review of a pre-specified interim safety report of the first three patients treated in the trial. The Company intends to recommence patient recruitment immediately, on the back of tremendous clinical interest in continuing the trial.

Read more here.